Exercise challenge: forced expiratory volume in one second (FEV1) parameters and pre-exercise exhaled nitric oxide (eNO) during the various study periods
| Maximum % fall in FEV1 | eNO ppb | |
| Subjects n | 25 | 25 |
| Run-in | 31.0±15.3 (24.7–37.3) | 16.0±10.1 (11.8–20.2) |
| Placebo | 27.9±15.6 (21.4–34.3) | 14.4±9.3 (10.5–18.4) |
| HFA-BDP 50 µg | 20.8±11.2 (16.2–25.4) | 9.3±6.8 (6.5–12.1) |
| HFA-BDP 100 µg | 20.9±13.1 (15.5–26.4) | 8.9±6.6 (6.2–11.6) |
| Pairwise differences | ||
| 50 µg and placebo | −7.0±16.6 (−13.9–−0.2) | −5.0±6.8 (−7.9–−2.1) |
| 100 µg and placebo | −6.9±13.4 (−12.4–−1.4) | −5.4±7.2 (−8.5–−2.4) |
| 100 µg and 50 µg | 0.1±15.5 (−6.2–6.5) | −0.4±3.5 (−1.8–1.0) |
| p-Values of effects | ||
| Treatment | 0.0387 | <0.0001 |
| Period | 0.2228 | 0.8349 |
| Carry-over | 0.1308 | 0.2022 |
Data are presented as n and mean±sd (95% confidence interval). ppb: parts per billion; HFA-BDP: hydrofluoroalkane-beclomethasone dipropionate